NCT01851642 Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
| NCT ID | NCT01851642 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Florida |
| Condition | Alpha-1 Antitrypsin Deficiency |
| Study Type | OBSERVATIONAL |
| Enrollment | 220 participants |
| Start Date | 2007-08-09 |
| Primary Completion | 2032-07-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 220 participants in total. It began in 2007-08-09 with a primary completion date of 2032-07-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Male or female 18 years of age or older * Negative pregnancy test for women of childbearing potential * Hemoglobin \>12.5 g/dl measured on the day of participation * Negative urine nicotine test Exclusion Criteria: * Pregnancy or breastfeeding * Weight \< 50 kg * History of anemia requiring blood transfusions, erythropoietin supplementation, or iron supplementation within the past 36 months * Known hemoglobin \<12.5 g/dl within the past 90 days * Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \>100 mmHg * Poor venous access * Large volume blood donation (\>200 ml or 7 ounces) within the previous 56 days (e.g. blood donation for the purposes of blood banking) * Clinically significant cardiac, hemostatic or neurological impairment or any other significant medical condition that, in the opinion of the investigator would affect subject safety (e.g., recent myocardial infarction, history of prolonged bleeding time, cerebral vascular accident, advanced cancer or uncontrolled medical condition) * Psychiatric or cognitive disturbance or illness that would affect subject safety * Current smoker
Contact & Investigator
Karina Serban, MD
PRINCIPAL INVESTIGATOR
University of Florida, College of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine
Frequently Asked Questions
Who can join the NCT01851642 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alpha-1 Antitrypsin Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01851642 currently recruiting?
Yes, NCT01851642 is actively recruiting participants. Contact the research team at Allison.Faunce@medicine.ufl.edu for enrollment information.
Where is the NCT01851642 trial being conducted?
This trial is being conducted at Gainesville, United States.
Who is sponsoring the NCT01851642 clinical trial?
NCT01851642 is sponsored by University of Florida. The principal investigator is Karina Serban, MD at University of Florida, College of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine. The trial plans to enroll 220 participants.